Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Tao, Rong"'
Autor:
Yongqi Deng, Yuan Tian, Tao Rong, Xiangdong Gan, Shuai Qin, Yuanqi Zhou, Xiaomei Wang, Yanlin Jia
Publikováno v:
Cancer Research. 83:2330-2330
Background: It is known that tumors with more infiltrated immune cells have better responses to PD-1/PD-L1 antibody therapy. PGE2 is involved in the regulation of the cancer microenvironment and tumor growth, mainly through the EP4 receptor. Inhibiti
Autor:
Douglas D. Fang, Na Li, Tao Rong, Jiaxing Gu, Jing Deng, Qixin Wang, Dengkun Xiong, Dajun Yang, Xu Fang, Yanhui Kong, Yifan Zhai, Qiuqiong Tang, Yan Yin
Publikováno v:
Cell Death Discovery
Cell Death Discovery, Vol 7, Iss 1, Pp 1-15 (2021)
Cell Death Discovery, Vol 7, Iss 1, Pp 1-15 (2021)
Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous clonal disease associated with unmet medical needs. Paralleling the pathology of other cancers, AML tumorigenesis and propagation can be ascribed to dysregulated cellular proc
Publikováno v:
Chemico-biological interactions. 325
Increasing studies have well-documented the involvement of numerous lncRNAs in regulating the malignant phenotypes of various tumors including non-small cell lung cancer (NSCLC) cells. However, up to date, the effects and mechanism of lncRNA amine ox
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 125, Iss, Pp 109856-(2020)
Lung cancer remains a big threat to human health. Growing evidence has reported the crucial regulatory effect of lncRNAs on NSCLC progression. Nevertheless, the detailed function of lncRNA MBNL1-AS1 involved in NSCLC development is poorly known. In o
Autor:
Qiuqiong Tang, Qixin Wang, Dajun Yang, Douglas D. Fang, Tao Rong, Yifan Zhai, Jing Deng, Yanhui Kong
Publikováno v:
Cancer Research. 81:981-981
The AML treatment landscape has improved dramatically in the past decade, with improved objective response rates and overall survival after treatment with newly approved targeted therapies. BCL-2 inhibition combined with a hypomethylating agent or lo
Autor:
Dajun Yang, Jiaxing Gu, Xu Fang, Peng Zou, Douglas D. Fang, Tao Rong, Qixin Wang, Qiuqiong Tang, Jingwen Wang, Yifan Zhai, Yanhui Kong
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-16 (2019)
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-16 (2019)
Background Programmed death-1 (PD-1) immune checkpoint blockade has achieved clinical successes in cancer therapy. However, the response rate of anti-PD-1 agents remains low. Additionally, a subpopulation of patients developed hyperprogressive diseas
Autor:
Qixin Wang, Xu Fang, Guangfeng Wang, Tao Rong, Douglas D. Fang, Yanhui Kong, Dajun Yang, Jiaxing Gu, Qiuqiong Tang, Yifan Zhai, Na Li
Publikováno v:
Cancer Research. 80:4217-4217
HQP1351 is a novel, orally bioavailable multi-kinase inhibitor targeting BCR-ABL, KIT, and FLT3. Currently, HQP1351 is in phase II clinical trials in relapsed and refractory chronic myeloid leukemia (CML) patients by targeting BCR-ABL. Besides, HQP13
Publikováno v:
Signal Transduction and Targeted Therapy
Obesity is a worldwide epidemic and results from excessive energy intake or inefficient energy expenditure. It is promising to utilize the thermogenic function of brown adipose tissue for obesity intervention. However, the mechanisms controlling the
Autor:
Jiaxing Gu, Qixin Wang, Xu Fang, Douglas D. Fang, Yanhui Kong, Jingwen Wang, Yifan Zhai, Tao Rong, Dajun Yang, Peng Zou, Qiuqiong Tang
Publikováno v:
Cancer Research. 79:3192-3192
Blockade of the checkpoint inhibitor programmed death 1 (PD-1) has gained big success in cancer therapy. However, the response rate of anti-PD1 agents remains low. Molecularly targeted agents offer selectivity and high tumor response rates, but patie